Home/Filings/4/0001193125-25-230508
4//SEC Filing

Patel Naimish 4

Accession 0001193125-25-230508

CIK 0001674416other

Filed

Oct 2, 8:00 PM ET

Accepted

Oct 3, 5:37 PM ET

Size

5.4 KB

Accession

0001193125-25-230508

Insider Transaction Report

Form 4
Period: 2025-10-03
Patel Naimish
Chief Medical Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2025-10-03+16,50016,500 total
    Exercise: $67.74Exp: 2035-10-03Common Shares (16,500 underlying)
Footnotes (1)
  • [F1]This option was granted on October 3, 2025 with respect to 16,500 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 3, 2025.

Documents

1 file

Issuer

CRISPR Therapeutics AG

CIK 0001674416

Entity typeother

Related Parties

1
  • filerCIK 0002021679

Filing Metadata

Form type
4
Filed
Oct 2, 8:00 PM ET
Accepted
Oct 3, 5:37 PM ET
Size
5.4 KB